new_0222_0359|PRLD|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0359|PRLD|1|Prelude Therapeutics Inc Total Current Assets (Quarterly) (USD)|Prelude Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Prelude Therapeutics Inc Inventories (Quarterly) (USD)|Prelude Therapeutics Inc Net PP&E (Quarterly) (USD)|Prelude Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Prelude Therapeutics Inc Total Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Deposits (Quarterly) (USD)|Prelude Therapeutics Inc Book Value (Quarterly) (USD)|Prelude Therapeutics Inc Retained Earnings (Quarterly) (USD)|Prelude Therapeutics Inc Treasury Stock (Quarterly) (USD)|Prelude Therapeutics Inc EV to Revenues|Prelude Therapeutics Inc EV to Earnings|Prelude Therapeutics Inc EV to Free Cash Flow|Prelude Therapeutics Inc EV to Assets (Quarterly)|Prelude Therapeutics Inc PS Ratio|Prelude Therapeutics Inc PE Ratio|Prelude Therapeutics Inc Price to Book Value|Prelude Therapeutics Inc PEG Ratio|Prelude Therapeutics Inc Debt to Equity Ratio|Prelude Therapeutics Inc Dividend Yield|Prelude Therapeutics Inc Shareholder Yield (TTM)|Prelude Therapeutics Inc Percent of Shares Outstanding Short|Prelude Therapeutics Inc Total Receivables (Quarterly) (USD)|Prelude Therapeutics Inc Total Payables (Quarterly) (USD)|Prelude Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Return on Invested Capital|Prelude Therapeutics Inc Quality Ratio Score|Prelude Therapeutics Inc Momentum Score|Prelude Therapeutics Inc Beta (1Y)|Prelude Therapeutics Inc Sustainable Growth Rate (TTM)|Prelude Therapeutics Inc Institutional Investor Ownership Percentage|Prelude Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Prelude Therapeutics Inc Total Employees (Annual)|Prelude Therapeutics Inc EPS Diluted (Quarterly) (USD)|Prelude Therapeutics Inc Shares Outstanding|Prelude Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Ordinary Shares Number (Quarterly)|Prelude Therapeutics Inc Payout Ratio|Prelude Therapeutics Inc Quick Ratio (Quarterly)|Prelude Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Prelude Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Prelude Therapeutics Inc Effective Tax Rate (TTM)|Prelude Therapeutics Inc Return on Equity|Prelude Therapeutics Inc Net Income (TTM) (USD)|Prelude Therapeutics Inc Revenue (TTM) (USD)|Prelude Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Prelude Therapeutics Inc Revenue (Quarterly) (USD)|Prelude Therapeutics Inc Gross Profit (Quarterly) (USD)|Prelude Therapeutics Inc SG&A Expense (Quarterly) (USD)|Prelude Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Interest Income (Quarterly) (USD)|Prelude Therapeutics Inc Price (USD)|Prelude Therapeutics Inc Total Return Price (USD)|Prelude Therapeutics Inc Enterprise Value (USD)|Prelude Therapeutics Inc 30-Day Average Daily Volume|Prelude Therapeutics Inc 1 Year Price Returns (Daily)||
new_0222_0359|PRLD|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0359|PRLD|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0359|PRLD|5|106.5|106.5||106.5||106.5|106.5|106.5||106.5|106.5||||1.44912280702||||1.44571428571|||1.44886363636||15.25||106.5|106.5|||30.6666666667|30.75|||91.375|91.4|91.375|25.5625||106.5|||91.375|91.3333333333|||91.4|||||91.375|91.375|91.375||1.44759206799|1.44759206799|1.44886363636|1.4520123839|1.43||
new_0222_0359|PRLD|6|6|6||6||6|6|6||6|6||||285||||350|||352||32||6|6|||3|4|||8|5|8|16||6|||8|6|||5|||||8|8|8||353|353|352|323|100||
new_0222_0359|PRLD|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0359|PRLD|201909||||||||||||||||||||||||||||||||||32.4018||-0.2078||||||-0.2078|||||||||1.394|-6.734|-6.734||||||||
new_0222_0359|PRLD|201912|20.224|18.879||1.647||71.283|4.835|66.448||-49.412|-50.497|||||||||||||||1.974||||||||32.4018||-0.3098|||42.4546|||-0.3098|||||||||1.246|-10.039|-10.039||||||||
new_0222_0359|PRLD|202003||||||||||||||||||||||||||||||||||32.4018||-0.2935||||||-0.2935|||||||||1.201|-9.511|-9.511||||||||
new_0222_0359|PRLD|202006|30.697|29.716||1.575||102.058|5.639|96.419||-69.311|-71.416|||||||||||||||3.471||||||||42.4546|51|-0.2687|||42.4546|||-0.2687||||-37.692|||||1.66|-11.408|-11.408||||||||
new_0222_0359|PRLD|202009|238.061|234.792||1.62||11.374|11.359|0.015||228.307|-88.176||||||||5.7676|||||0.0132||5.074|0.004||||||85.9318|3.1945|55|-5.25|43.7034||43.7034|||-5.25|-167.929|||-47.718|||||2.851|-16.76|-16.76||30.13|30.13|1081.9914|117394.5333||35.23|51.47
new_0222_0359|PRLD|202012|220.809|218.309||2.48||11.407|11.375|0.032||212.183|-107.426||||-62.1572||||14.738|||||2.8086||3.92|0.004|||||||43.7057|68|-0.4404|43.7057||43.7057|||-0.4404|1.299|||-56.929|||||4.874|-19.25|-19.25||71.55|71.55|2908.8338|195008.9667||64.95|62.33
new_0222_0359|PRLD|202103|365.018|362.99||4.813||13.264|12.424|0.84||356.567|-128.726||||-30.8656||||5.686|||||3.6742||4.842|0.005|||||||45.122|105|-0.47|46.7909||46.7909|||-0.47|-161.424|||-68.718|||||5.497|-21.3|-21.3||43.33|43.33|1664.4597|200349.4333||41.44|34.76
new_0222_0359|PRLD|202106|344.575|343.119||5.006||15.22|14.677|0.543||334.361|-155.591||||-15.3749||||4.0277|||||7.231||6.844|0.005|||||||46.0571|100|-0.58|47.0387||47.0387|||-0.58||||-84.175|||||5.513|-26.865|-26.865||28.63|28.63|1003.599|224939.7||32.04|35.69
new_0222_0359|PRLD|202109|325.897|320.865||5.32||19.975|19.663|0.312||311.242|-186.278||||-15.3787||||4.7383|||||9.4094||11.062|0.005|||4|2.5212|||46.3308|113|-0.66|47.1918||47.1918|||-0.66||||-98.102|||||8.115|-30.687|-30.687||31.25|31.25|1153.8788|354084.1|3.7172|17.58|14.29
new_0222_0359|PRLD|202112|||||||||||||||-3.5581||||1.8887|||||10.8962||||||1|-1.1063||||||||||||||||||||||||12.45|12.45|266.9667|468497.9333|-82.5996|9.93|9.91